Evidence map›Paper›PMID 32012917›Full record

ReviewCells2020

From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer.

Chiara Bazzichetto, Fabiana Conciatori, Claudio Luchini, Francesca Simionato, Raffaela Santoro, Vanja Vaccaro, Vincenzo Corbo, Italia Falcone, Gianluigi Ferretti, Francesco Cognetti and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Translational cancer research · 2022
    Article
  9. Article
  10. Nanoparticle-based immunotherapy of pancreatic cancer.Frontiers in molecular biosciences · 2022
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Chiara BazzichettoMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Fabiana ConciatoriMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology, University and Hospital Trust of Verona, 37134 Verona, Italy.
Francesca SimionatoDivision of Oncology, University of Verona, 37126 Verona, Italy.
Raffaela SantoroMedicine-Digestive Molecular Clinical Oncology Research Unit, University of Verona, 37126 Verona, Italy.
Vanja VaccaroMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Vincenzo CorboARC-Net Research Centre, University and Hospital Trust of Verona, 37126 Verona, Italy.
Italia FalconeMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Gianluigi FerrettiMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Francesco CognettiMedical Oncology 1, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Davide MelisiMedicine-Digestive Molecular Clinical Oncology Research Unit, University of Verona, 37126 Verona, Italy.
Aldo ScarpaARC-Net Research Centre, University and Hospital Trust of Verona, 37126 Verona, Italy.
Ludovica CiuffredaSAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Michele MilellaDivision of Oncology, University of Verona, 37126 Verona, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The threatening notoriety of pancreatic cancer mainly arises from its negligible early diagnosis, highly aggressive progression, failure of conventional therapeutic options and consequent very poor prognosis. The most important driver genes of pancreatic cancer are the oncogene

Indexed as

AnimalsCarcinogenesisClinical Trials as TopicHumansPancreatic NeoplasmsSignal TransductionTumor Microenvironmentoncogenepancreatic cancersignaling pathwaytargeted therapytumor microenvironmenttumor suppressor

Identifiers

PMID32012917
PMCPMC7072496
OpenAlexW3003979238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.